Your browser doesn't support javascript.
loading
Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy.
Liu, S; Zha, J; Lei, M.
Afiliação
  • Liu S; Department of Ultrasound, The People's Hospital of Three Gorges University, The First People's Hospital of Yichang, Yichang, 443000, China. latte201217@163.com.
  • Zha J; Department of Obstetrics and Gynecology, The People's Hospital of Three Gorges University, The First People's Hospital of Yichang, Yichang, 443000, China.
  • Lei M; Department of Obstetrics and Gynecology, The People's Hospital of Three Gorges University, The First People's Hospital of Yichang, Yichang, 443000, China.
Clin Transl Oncol ; 20(3): 374-381, 2018 Mar.
Article em En | MEDLINE | ID: mdl-28766096
PURPOSE: To investigate whether ERK/MNK/eIF4E contributes chemoresistance in ovarian cancer. METHODS: The phosphorylated levels of Erk, Mnk, and eIF4E were systematically analyzed in ovarian cancer patients before and after chemotherapy, and ovarian cancer cells exposed to short- and long-term chemo-agent treatment. The roles of Erk/Mnk/eIF4E were investigated using pharmacological and genetic approaches. RESULTS: Increased phosphorylation levels of ERK, Mnk1, and eIF4E were observed in ovarian cancer cell exposed to chemotherapeutic agents, and paclitaxel-resistant SK-OV-3-r cells, and is a common response of ovarian cancer patients undergoing chemotherapy. MEK inhibitor U0126 inhibits basal and chemodrug-induced phosphorylation of ERK as well as Mnk1 and eIF4E, suggesting that Mnk1/eIF4E are the downstream signaling of ERK pathway and chemotherapy agents activate ERK/MNK/eIF4E in a MEK-dependent manner. eIF4E overexpression promotes ovarian cancer cell growth without affecting migration. In addition, ovarian cancer cells with eIF4E overexpression are more resistant to chemotherapeutic agents in aspect of growth inhibition and apoptosis induction compared to control cells. In contrast, eIF4E depletion augments chemotherapeutic agents' effect in ovarian cancer cells. These demonstrate that eIF4E play roles in growth and chemoresistance in ovarian cancer. MEK inhibitor U0126 also significantly enhances chemotherapeutic agents' inhibitory effects. CONCLUSIONS: Our work shows that ERK/Mnk/eIF4E activation is critically involved in ovarian cancer chemoresistance and inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Proteínas Serina-Treonina Quinases / Resistencia a Medicamentos Antineoplásicos / Proteínas de Transporte Nucleocitoplasmático / Peptídeos e Proteínas de Sinalização Intracelular / ATPases Transportadoras de Cobre Limite: Female / Humans Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: China País de publicação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Proteínas Serina-Treonina Quinases / Resistencia a Medicamentos Antineoplásicos / Proteínas de Transporte Nucleocitoplasmático / Peptídeos e Proteínas de Sinalização Intracelular / ATPases Transportadoras de Cobre Limite: Female / Humans Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: China País de publicação: Itália